Archive · 1 Aug 2025
FDA Vaccine Chief Vinay Prasad Resigns After Short Tenure
Dr. Vinay Prasad, who was in charge of vaccines at the FDA, is leaving his job after only a few months.
This happened because he was getting a lot of complaints from people, including those who make medicines and patient groups.
He was also criticized for some decisions he made about a new medicine for a muscle disease.
Prasad had previously questioned how the FDA approves medicines.
Now, another doctor, George Tidmarsh, will take over his job temporarily.
Dr. Vinay Prasad is leaving the FDA after a short tenure as vaccine chief.
Prasad's departure was announced after drawing criticism from various groups.
He faced scrutiny for his handling of a gene therapy for Duchenne's muscular dystrophy.
Prasad had criticized the FDA's approach to drug approvals and COVID-19 vaccines.
Dr. George Tidmarsh will take over Prasad's role as acting vaccine chief.
- Who
- Dr. Vinay Prasad and Dr. George Tidmarsh are the key individuals.
- What
- Dr. Vinay Prasad is leaving his position as the FDA's vaccine chief.
- When
- Prasad is leaving three months after his appointment.
- Where
- At the FDA.
- Why
- Prasad is leaving because he did not want to be a distraction and spend more time with his family.
Criticism of Prasad
Prasad's Stance
Drug Approval Standards
Criticism of Prasad
Concerns raised by patient groups and biotech executives.
Prasad's Stance
Support for speedier approvals and access to experimental treatments.
Gene Therapy for Duchenne's muscular dystrophy
Criticism of Prasad
Prasad's handling of the gene therapy for Duchenne's muscular dystrophy was criticized
Prasad's Stance
Families of patients with the disease pushed back against the pause of gene therapy.
- Position
- FDA Vaccine Chief
- Departure Date
- Within 3 months of appointment
- Successor
- Dr. George Tidmarsh (Acting)
- Prior Affiliation
- University of California San Francisco
- Controversy
- Handling of gene therapy for Duchenne's
- Criticism
- FDA's approach to drug approvals